On July 17, 2023, The U.S. Food and Drug Administration (FDA) approved Beyfortus™, a long-acting antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in all infants born during or entering their first RSV season and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Here is the full press release with additional information.